January 2017 FDA Recall Drug by Actavis Inc
D-0476-2017 - Failed Dissolution Specifications. Above out of specification for dissolution rate observed at the 10 hour testing point.

This Class II drug recall was voluntarily initiated by Actavis Inc on January 30, 2017 for the product Drug. The FDA reported the reason for recall as failed dissolution specifications. above out of specification for dissolution rate observed at the 10 hour testing point.. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0476-2017

Reason for Recall
Failed Dissolution Specifications. Above out of specification for dissolution rate observed at the 10 hour testing point.
Initiated
01-30-2017
Reported
02-22-2017
Quantity
499320 units

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Glipizide extended-release tablets, 2.5mg, 30-count bottle, Rx Only, Manufactured By Patheon Pharmaceuticals Inc Cincinnati OH 45237 USA, NDC 0591-0900-30, UPC 3-0591090030-4

Batch or Lot Expiration Information

Lot# : 3134201, 3134202, Exp. 06/30/17; 3134319, Exp. 05/31/17; 3135246, Exp. 07/31/17; 3135247, 3136781, Exp. 08/31/17; 3136782, Exp. 09/30/17; 3136903, 3136904, Exp.10/31/17; 3138250, Exp. 07/31/17; 3138968, Exp. 08/31/17; 3140000, Exp. 09/30/17